<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01716611</url>
  </required_header>
  <id_info>
    <org_study_id>KUH1010412</org_study_id>
    <nct_id>NCT01716611</nct_id>
  </id_info>
  <brief_title>Tolvaptan for Hyponatremia in Cirrhotic Patients With Ascites</brief_title>
  <acronym>TONIC</acronym>
  <official_title>Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Inje University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea University Anam Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hanyang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Seoul St. Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hallym University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Inha University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Incheon St.Mary's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chungnam National University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate the efficacy and safety for the management of&#xD;
      hyponatremia and ascites in patients with liver cirrhosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with advanced cirrhosis frequently develop dilutional hyponatremia due to impairment&#xD;
      of their renal ability to eliminate solute-free water. Although the pathophysiology of this&#xD;
      disorder is multifactorial, an increased hypersecretion of arginine vasopressin (AVP) is a&#xD;
      major factor. The prevalence of hyponatremia in cirrhosis, as defined by a serum sodium level&#xD;
      of 130 mmol/L is reported to be about 20%, and there are several lines of evidence that&#xD;
      hyponatremia is a risk factor for the development of hepatic encephalopathy, and that it&#xD;
      predicts a poor quality of life independent of liver function. Hyponatremia also predicts&#xD;
      short-term mortality in cirrhotic patients awaiting liver transplantation. The principle of&#xD;
      the management of hypervolemic hypona- tremia is to induce a negative water balance, with the&#xD;
      aim of normalizing the increased total body water, which would result in an improvement in&#xD;
      serum sodium concentration. Fluid restriction is the most widely accepted nonpharmacological&#xD;
      therapy, but its efficacy is very limited. The administration of hypertonic sodium chloride&#xD;
      has been common in severe hypervolemic hyponatremia, but its effect is only partial and short&#xD;
      lived; moreover, additional expansion of fluid can worsen ascites and edema. Therefore, the&#xD;
      pathophysiologically oriented treatment of hyponatremia focuses on inhibiting the actions of&#xD;
      AVP. Recently, antagonists of the V2 receptors of vasopressin has been proposed to manage&#xD;
      hyponatremic patients, such as heart fauilure, syndrome of inappropriate antidiuretic hormone&#xD;
      or liver cirrhosis. Especially, a lot of hyponatremic patients with cirrhosis had ascites,&#xD;
      and some of them had intractable ascites. In these patients, antagonists of the V2 receptors&#xD;
      of vasopressin including tolvaptan might have beneficial effect in enhancing not only&#xD;
      hyponatremia , but also ascites&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 28 after intervention</measure>
    <time_frame>baseline and 28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the change in the average daily area under the curve (AUC) for the serum sodium concentration from baseline to day 4</measure>
    <time_frame>baseline and 4 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to normalization of the serum sodium concentration</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to first paracentesis, number of paracentesis, the volume of ascitic fluid obtained from paracentesis</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Abdominal discomfort based on a 100-mm visual analogue scales (VAS)</measure>
    <time_frame>day 1, 2, 3, 4, 7, 14, 21, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in the dose of concomitant diuretics from baseline at day 28</measure>
    <time_frame>day 1, 2, 3, 4, 7, 14, 21, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the number of participants with serious adverse events</measure>
    <time_frame>from baseline to day 28 after intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time to ascites improvement</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the time of worsening of ascites</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Hyponatremia</condition>
  <condition>Ascites</condition>
  <arm_group>
    <arm_group_label>Tolvaptan group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Form : Tablet, Dosage: 15 mg, 30 mg or 60 mg, Frequency: once a day. Duration: 28days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>15 - 60 mg/day for 28 days</description>
    <arm_group_label>Tolvaptan group</arm_group_label>
    <other_name>SAMSCA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 20 years of age or older&#xD;
&#xD;
          2. Patients with cirrhosis as diagnosed by liver biopsy or a combination of laboratory&#xD;
             (thrombocytopenia), radiologic (cirrhotic feature of liver, splenomegaly, collateral&#xD;
             shunt on US, CT, or MRI) and endoscopic findings (gastoesophageal varices or portal&#xD;
             hypertensive gastropathy)&#xD;
&#xD;
          3. ≥ Grade 2 ascites who have already been treated with restricted salt diet within 3&#xD;
             month&#xD;
&#xD;
          4. Hyponatremia (Serum sodium ≥120 mEq/L and ≤130 mEq/L)&#xD;
&#xD;
          5. Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypovolemic hyponatremia (Patients with hypotension or chronic heart failure)&#xD;
&#xD;
          2. Serum potassium concentration &gt; 5.5 mEq/L&#xD;
&#xD;
          3. Serum bilirubin &gt; 5.0 mg/dL&#xD;
&#xD;
          4. Blood coagulation factor &lt; 40% or international normalized ratio (INR) &gt; 2.3&#xD;
&#xD;
          5. Platelet count &lt; 30,000/mm3&#xD;
&#xD;
          6. Serum creatinine &gt; 3 mg/dL&#xD;
&#xD;
          7. Treatment within 2 weeks with vasopressin anlogues&#xD;
&#xD;
          8. Systolic blood pressure &lt;80 mmHg&#xD;
&#xD;
          9. History of gastrointestinalesophageal varix bleeding variceal hemorrhage&#xD;
&#xD;
         10. Spontaneous bacterial peritonitis&#xD;
&#xD;
         11. Hepatic encephalopathy ≥ grade 3&#xD;
&#xD;
         12. History of Hepatocellular carcinoma treatment within 3month or viable tumor Viable&#xD;
             hepatocellular carcinoma&#xD;
&#xD;
         13. Liver transplant&#xD;
&#xD;
         14. Previous treatment with transjugular intrahepatic portosystemic stent shunt (TIPS)&#xD;
&#xD;
         15. History of significant cardiac diseases such as recent myocardial infarction or&#xD;
             ischemic diseases within 1 year of screening&#xD;
&#xD;
         16. Prolonged QTc interval of &gt; 500 ms based on electrocardiography&#xD;
&#xD;
         17. Treatment within 2 weeks with substances or drugs that may either induce or&#xD;
             significantly inhibit cytochrome P450 3A (ketoconazole, clarithromycin, erythromycin,&#xD;
             fluconazole, diltiazem, verapamil, etc)&#xD;
&#xD;
         18. Pregnant or breast feeding&#xD;
&#xD;
         19. Patients with galactose intolerance or malabsorption (as production of the drug&#xD;
             contains lactose)&#xD;
&#xD;
         20. HbA1Cc ≥ 9 %&#xD;
&#xD;
         21. Serious medical illness (e.g. heart failure, severe pulmonary disorders, alcohol&#xD;
             dependence, malignant tumors, etc)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>June Sung Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Won Hyeok Choe, MD</last_name>
    <phone>82-2-2030-7506</phone>
    <email>20050101@kuh.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <contact>
      <last_name>Won Hyeok Choe, MD</last_name>
      <phone>82-2-2030-5027</phone>
      <email>20050101@kuh.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2012</study_first_posted>
  <last_update_submitted>October 29, 2012</last_update_submitted>
  <last_update_submitted_qc>October 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Won Hyeok Choe</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>hyponatemia</keyword>
  <keyword>ascites</keyword>
  <keyword>vaptans</keyword>
  <keyword>antidiuretic hormon</keyword>
  <keyword>arginine vasopressin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyponatremia</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

